Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT + apatinib + sintilimab first-line treatment for stage IV gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200063761Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin, folinic acid, fluorouracil, Rivoceranib and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Hospital of Lanzhou University. Primary endpoints: progression-free survival and overall survival. Started Aug 2022; status: recruiting.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracilRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200063761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063761.